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A B S T R A C T
Studies to identify novel immune-regulatory functions of active vitamin D (1,25(OH)2D3) in human CD4+ T cells
revealed that 1,25(OH)2D3 potently induced expression of the gene SERPINA1, encoding the anti-protease α-1-
antitrypsin. We conﬁrmed α-1-antitrypsin protein expression by 1,25(OH)2D3-treated CD4+ T cells, but not in
CD8+ T cells or monocytes. α-1-Antitrypsin promotes anti-inﬂammatory IL-10 synthesis in other immune cell
populations. We therefore investigated its immune-regulatory eﬀects in CD4+ T cells. Plasma-derived α-1-an-
titrypsin drove IL-10 synthesis by CD4+ T cells, which was not dependent on anti-protease activity, but appeared
to require a serum-binding factor, since this could not be achieved with recombinant protein. α-1-Antitrypsin is
reported to bind complement components, which regulate T cell function. A role for this interaction was
therefore probed. Plasma-derived, but not recombinant α-1-antitrypsin contained C3a. Surface Plasmon
Resonance and Microscale Thermophoresis demonstrated α-1-antitrypsin binding to C3a. Addition of C3a to
CD4+ T cells cultured with recombinant α-1-antitrypsin restored induction of IL-10, whereas neutralisation of
C3a abrogated IL-10 induced by plasma-derived α-1-antitrypsin. To interrogate an endogenous role for the α-1-
antitrypsin-C3a axis in 1,25(OH)2D3-driven CD4+ T cell IL-10 synthesis, we treated cells from healthy or α-1-
antitrypsin-deﬁcient individuals (which transcribe SERPINA1 but do not secrete protein) with 1,25(OH)2D3. A
signiﬁcant correlation was identiﬁed between SERPINA1 and IL10 gene expression in healthy donor CD4+ T
cells, which was absent in cells from α-1-antitrypsin-deﬁcient individuals. Therefore, α-1-antitrypsin is required
for 1,25(OH)2D3-induced IL-10 expression in CD4+ T cells, interacting with C3a to drive IL-10 expression.
1. Introduction
Vitamin D is a potent anti-inﬂammatory mediator, with its active
form (1,25-dihydroxyvitamin D, 1,25(OH)2D3) having a range of im-
mune-regulatory functions including direct induction of anti-microbial
functions and the generation of tolerogenic antigen presenting cells and
regulatory T cells [1]. Eﬀects of 1,25(OH)2D3 on CD4+ ‘helper’ T cells,
which co-ordinate the immune response have been a particular interest
of our laboratory and previous work has identiﬁed 1,25(OH)2D3-
mediated induction of the anti-inﬂammatory cytokine IL-10, the im-
mune-suppressive ligand CD200 and the regulatory T cell hallmark
transcription factor FoxP3 [2–5]. The induction of inhibitory antigens
such as CTLA4, ﬁrst described by Jeﬀery et al. [6], occur rapidly in
culture and likely represent direct transcriptional regulation by
1,25(OH)2D3. In contrast, evidence exists that 1,25(OH)2D3 controls
synthesis of the anti-inﬂammatory cytokine IL-10, with positive corre-
lations seen in vivo [4,7]. However the capacity of 1,25(OH)2D3 to
induce IL-10 synthesis by CD4+ T cells occurs comparatively slowly in
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culture [4], and it seems probable that this may represent an indirect
eﬀect, requiring signals from additional cells and/or 1,25(OH)2D3-in-
duced mediators.
Alpha-1-antitrypsin (α-1-antitrypsin) is a key inhibitor of neutrophil
elastase with particular relevance in the airways. Variant alleles of α-1-
antitrypsin predispose to conformational change in the protein, poly-
merisation and retention within the endoplasmic reticulum, and a
concomitant deﬁciency of protein. Its key anti-protease role in the
airway is evidenced by the fact that α-1-antitrypsin-deﬁciency re-
presents the only established heritable cause of chronic obstructive
pulmonary disease (COPD) caused by excessive elastolytic activity and
tissue damage [8]. However, native α-1-antitrypsin additionally has
independent anti-inﬂammatory properties, with reported eﬀects in
vitro on neutrophil chemotaxis, monocyte and dendritic cell maturation
and cytokine proﬁles [9]. Consistent with this, in animal models of
autoimmunity and transplantation, human α-1-antitrypsin is protective,
with evidence for induction of immune-regulatory pathways [10,11].
Associations exist between reduced α-1-antitrypsin expression and/or
function and a number of human diseases of immune dysregulation
[10]. As yet these properties of α-1-antitrypsin are not fully understood,
but the cytokine IL-10 may play a key role. Human innate immune cells
produce IL-10 in response to α-1-antitrypsin in vitro, COPD progression
in α-1-antitrypsin deﬁciency associates with IL-10 polymorphisms and
α-1-antitrypsin replacement therapy increases circulating IL-10 in those
individuals [12].
This study investigated whether vitamin D (1,25(OH)2D3) controls
gene and protein expression for α-1-antitrypsin in human peripheral T
cells. Subsequent studies investigated whether this represents a direct
action of α-1-antitrypsin, or whether additional co-factors are required,
as well as whether α-1-antitrypsin may be required for the immune
regulatory functions, speciﬁcally IL-10 induction, of 1,25(OH)2D3.
2. Materials and methods
2.1. Patient details
Peripheral blood was obtained from healthy volunteers or in-
dividuals with diagnosed α-1-antitrypsin deﬁciency (PiZZ) attending
the London Alpha-1 Antitrypsin Deﬁciency Service, UCL/The Royal
Free Hospital. All volunteers signed a consent form and all studies were
fully approved by the NRES research committee (London) (REC re-
ference 14/LO/1699 for healthy donors and 13/LO/1085 for α-1-an-
titrypsin-deﬁcient individuals).
For the data in Fig. 5 volunteer demographics were: Healthy sub-
jects (aged 25–62, 5:4 female:male ratio); α-1-antitrypsin-deﬁcient
(PiZZ) individuals (25–74 years, 3:7 female:male ratio). PiZZ in-
dividuals had not received α-1-antitrypsin replacement therapy.
2.2. Cell puriﬁcation and culture
Cell puriﬁcation from peripheral blood was performed as previously
described [4]. Puriﬁed T cells (1× 106 cells/ml, in AIM-V serum-free
medium, or RMPI medium plus 10% foetal calf serum (FCS); both Life
Technologies Ltd.– indicated in the ﬁgure legend) were stimulated with
1 μg/ml plate-bound anti-CD3 (OKT-3, in-house) and 2 μg/ml plate-
bound anti-CD28 (CD28.2, BD Biosciences, San Diego, CA) and 50U/ml
IL-2 (Eurocetus, Hareﬁeld, UK). They were treated with α-1-antitrypsin
(at concentrations indicated), C3a (100 ng/ml, Complement Tech-
nology, Inc., Tyler, TX) or a titration of 1,25(OH)2D3 (10−9–10−7 M,
Enzo Life Sciences, USA). α-1-Antitrypsin protein samples were ob-
tained commercially (Sigma-Aldrich, UK) or puriﬁed in-house from
human plasma or an E. coli recombinant system. Other sources of gly-
cosylated recombinant protein were not used, since the functional ex-
periments with E. coli generated protein identiﬁed glycosylation not to
be required. In-house preparations were as described previously
[13,14] but with a modiﬁcation to the plasma protein puriﬁcation in
which the initial chromatography step was performed using an alpha-
select (GE Heathcare, US) column rather than thiol exchange. Ad-
ditionally in some cultures, neutralising anti-C3a (5 μg/ml, clone 2991,
gift from Professor Joerg Koehl, Lubeck University, Germany) was in-
cluded. Supernatants were harvested at time points indicated for ana-
lysis of cytokines and α-1-antitrypsin. Cell pellets were harvested at 14
for qPCR analysis of SERPINA1 gene expression. Puriﬁed monocytes
(1×106 cells/ml, in AIM-V serum-free medium, or RMPI medium plus
10% foetal calf serum; both Life Technologies Ltd) were unstimulated
or stimulated with lipopolysaccharide (LPS, 500 ng/ml, Sigma-Aldrich,
UK) for 48 h in the absence or presence of 1,25(OH)2D3 as indicated.
Supernatants were harvested at 48 h for α-1-antitrypsin analysis.
2.3. Cytokine analysis
Cytokine concentrations in cell culture supernatants were assessed
using the cytometric bead array (CBA) ﬂex-set, according to the man-
ufacturer’s instructions and using AIM-V serum-free medium as a di-
luent for standards (1 in 5 dilution of reagents, validated). Samples
were assayed using the BDFortessa or FACSCalibur ﬂow cytometer (BD,
UK). Data were analysed using FlowJo (version 9.2, TreeStar Inc) and
GraphPad Prism (version 5 for Mac OS X, GraphPad Software Inc.). The
lower limit of detection for all cytokines was 1.5 pg/ml.
2.4. qPCR
qPCR (real time RT-PCR) was performed as previously described
[4], in triplicate, using an Applied Biosystems 7900 HT system and a
FAM-labelled Assay-on-Demand reagent set for SERPINA1 :
Hs01097800_m1. Real time RT-PCR reactions were multiplexed using
VIC labelled 18 s primers and probes (Hs99999901_s1) as an en-
dogenous control and analyzed using SDS software version 2.1 (Applied
Biosystems), according to the 2-(ΔΔCt) method.
2.5. Alpha-1-antitrypsin ELISA
The α-1-antitrypsin ELISA employed a commercial polyclonal rabbit
anti-human α-1-antitrypsin primary antibody (DAKO, Cambridgeshire,
UK) and a biotinylated aﬃnity-puriﬁed rabbit anti-human α-1-anti-
trypsin secondary antibody. This was puriﬁed from rabbit antiserum
(Dade Behring, Marburg, Germany) using antitrypsin coupled to acti-
vated CH-Sepharose 4B beads (Amersham Bioscience, Pittsburgh, USA)
and conjugated with biotin using Pierce EZ-link NHS-LC Biotin® (Pierce,
Rockford, Illinois, USA). α-1-Antitrypsin standards were prepared in
RPMI medium plus 10% foetal calf serum, by serial 1:2 dilutions from
the top standard (200 ng/ml; prepared from human plasma-puriﬁed α-
1-antitrypsin, Sigma-Aldrich). ExtrAvidin® alkaline phosphatase en-
zyme (Sigma-Aldrich) and phospho-nitrophenylphosphate substrate
(Sigma-Aldrich) were used as a detection system. α-1-Antitrypsin levels
were measured using an Anthos HTII Plate reader (Anthos, UK) at an
absorbance at 405 nm and quantiﬁed using GraphPad Prism software
(version 5 for Mac OS X, GraphPad Software Inc.). The lower limit of
detection for this assay was 0.32 ng/ml.
2.6. Chymotrypsin activity assay
1–5 nM α-1 antitrypsin was pre-incubated with 1 μM α-chymo-
trypsin from bovine pancreas (Sigma, UK) made up to a total volume of
100 μl with reaction buﬀer (0.03MNa2HPO4, 160mM NaCl, 0.1%
PEG4K, pH7.4). The substrate for chymotrypsin, 0.1mM N-succinyl-
Ala-Ala-Pro-Phe P-nitroanilide (Sigma, UK) was added and absorbance
(405 nm) was read on the CARY UV spectrophotometer (Agilant
Technologies, USA) at 0min (T0) and after 10min (T10) incubation at
room temperature. Readings are plotted as normalised T10-T0 405 nm
absorbance against α-1-antitrypsin concentration.
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2.7. Surface plasmon resonance
SPR assays were conducted with a Biacore T200 instrument (GE
Healthcare). Speciﬁc binding surfaces were prepared by coupling pro-
tein diluted in sodium acetate buﬀer, pH 4.5, to the dextran matrix of
CM5 sensor chips using a Biacore Amine Coupling Kit. Biotinylated-C3a
(Complement Technology Inc., Texas, US) was produced using a pro-
tocol designed to haved no more than one biotin molecule per molecule
of C3a, by reacting protein with biotinamidohexanoic acid 3-sulfo-N-
hydroxysuccinimide ester sodium salt (Sigma-Aldrich) at a 3:1M ratio.
When commercially produced α-1-antitrypsin was used it was dissolved
to 10mg/ml in phosphate buﬀered saline (PBS) and ﬁltered using a
0.45 μm ﬁlter; size-exclusion chromatography (performed by Marie
Pang) was used to remove any α-1-antitrypsin aggregates. Assays re-
ported here typically used immobilization levels of 800–1500 re-
sonance units. Samples of serially diluted α-1-antitrypsin were injected,
and all measurements were performed at a continuous ﬂow rate of
10 μl/minute in sterile Dulbecco’s PBS buﬀer. Regeneration of ligand-
bound surfaces after binding of each potential ligand sample was
achieved using a single 60 s injection of 2.0 M KCl. Non-speciﬁc binding
was assessed by performing sample injections over a sensor surface that
underwent identical activation and blocking but with no ligand im-
mobilised. Nonspeciﬁc binding was subsequently subtracted from the
speciﬁc reaction prior to analysis. Data were analysed using the
Biaevaluation 3.1 analysis package (GE Healthcare).
2.8. Microscale thermophoresis
MST was performed using the Monolith NT.115 instrument
(NanoTemper-Technologies, Munich, Germany), with LED settings at
70% and MST power at 20%. NT-647 labeled AAT (NanoTemper-
Technologies, Munich, Germany) at 0.5 μM was incubated for 30min
with C3a at concentrations between 6 nM and 205 μM before loading in
standard MST capillary tubes for binding measurements.
2.9. Statistics
Results are presented either as individual results of independent
experiments or summarised as mean ± standard error of the mean
deviation (SEM) for normally distributed data or median ±
interquartile range (IQR) for non-normal data as indicated in the ﬁgure
legend. Summarised paired data were statistically tested by paired or
unpaired t-test or repeated measures ANOVA for normally distributed
data, or using the Wilcoxon, Mann–Whitney U or Friedman test for non-
normal data as indicated in speciﬁc ﬁgure legends. All p values were
corrected for multiple comparisons using the Bonferroni test or Dunns
test respectively. Diﬀerences were considered signiﬁcant at the 95%
conﬁdence level. All statistical analyses were carried out using
Graphpad Prism version 5.0 for Macintosh OS X.
3. Results
3.1. 1,25(OH)2D3 induces α-1-antitrypsin expression by human CD4+ T
cells
Preliminary studies to identify novel, unidentiﬁed immune-reg-
ulatory functions of 1,25(OH)2D3 in human CD4+ T cells, and to
identify potential mediators of 1,25(OH)2D3-induced anti-in-
ﬂammatory IL-10 expression, identiﬁed SERPINA1, encoding α-1-anti-
trypsin, as potently upregulated. qPCR analysis conﬁrmed
1,25(OH)2D3-upregulation of SERPINA1 (Fig. 1a) and ELISA conﬁrmed
α-1-antitrypsin protein secretion by these cells (Fig. 1b), although not
by 1,25(OH)2D3-treated CD8+ T cells studied under the same experi-
mental conditions (Fig. 1c). CD14+ monocytes produced α-1-anti-
trypsin constitutively and increased their secretion to similar levels to
CD4+ T cells when stimulated with LPS –in agreement with previous
reports [15]. However, monocytes did not respond to 1,25(OH)2D3 for
further upregulation. (Fig. 1d). We have therefore identiﬁed that
1,25(OH)2D3 promotes α-1-antitrypsin synthesis by human CD4+ T
cells – a novel cellular source of this protein.
3.2. Human plasma-derived α-1-antitrypsin increases CD4+ T cell IL-10
production
α-1-Antitrypsin is reported to have potent immune-regulatory ef-
fects in vivo, as well as on total peripheral blood mononuclear cells
(PBMC) and innate immune cell populations [9]. We were therefore
interested to deﬁne its eﬀects on human CD4+ T cells, which we have
identiﬁed produce this protein when stimulated in the presence of
1,25(OH)2D3 (Fig. 1). Initially, we assessed cytokine proﬁles of CD4+ T
cells stimulated in the presence of α-1-antitrypsin puriﬁed from human
plasma, using concentrations of α-1-antitrypsin similar to circulating
levels (in vitro doses of 10–1000 μg/ml are equivalent to 0.18–18 μM;
circulating levels are 20–48 μM). These experiments revealed that
human plasma-derived α-1-antitrypsin signiﬁcantly increased CD4+ T
cell IL-10 secretion (Fig. 2a). Enhanced secretion of IFN-γ (Fig. 2b), but
not TNF-α (Fig. 2c) or IL-13 (Fig. 2d) were also observed. CD4+ T cells
responded to α-1-antitrypsin for induction of IL-10 in a dose-dependent
manner from 10 to 1000 μg/ml with signiﬁcant eﬀects observed at
500 μg/ml and maximal eﬀects observed at 1mg/ml α-1-antitrypsin
(Supplementary Fig. 1). Commercial preparations of human plasma-
derived α-1-antitrypsin are known to contain non-native conformations
of the protein that are inactive as protease inhibitors [16]. We therefore
repeated our experiments, comparing human plasma α-1-antitrypsin
with a recombinant α-1-antitrypsin preparation, as well as a control for
exogenous protein addition (at the same concentration). These experi-
ments interestingly revealed that human plasma-derived, but not re-
combinant α-1-antitrypsin induced IL-10 (Fig. 2E) and IFN-γ (Fig. 2F)
secretion, whereas the protein control had little eﬀect on cytokine le-
vels. A chymotrypsin activity assay conﬁrmed that human plasma-de-
rived α-1-antitrypsin had very little anti-protease activity compared to
the recombinant preparation (Fig. 2G). Taken together, these data
suggest that the eﬀects of α-1-antitrypsin on cytokine secretion do not
require serine protease inhibitory activity, but may require a plasma-
derived molecule binding to α-1-antitrypsin –not present in the re-
combinant preparation. We next explored this possibility.
3.3. α-1-Antitrypsin directly binds to complement C3a
The complement system, and particularly the anaphylatoxins C3a
and C5a are produced by immune cells and regulate cytokine secretion,
particularly by CD4+ T cells [17]. Furthermore, α-1-antitrypsin has
previously been reported to interact with total C3 [18]. We therefore
explored whether these molecules may play a role in the induction of
cytokine secretion by human plasma-derived α-1-antitrypsin. In initial
experiments, we assessed whether C3a, C4a or C5a were present in the
diﬀerent α-1-antitrypsin preparations we employed. Indeed, C3a was
detected in the human plasma-derived α-1-antitrypsin, but not the re-
combinant preparation (Fig. 3a). C4a and C5a were detectable at lower
levels in the plasma-derived preparation only (Supplementary Fig. 2).
The capacity of α-1-antitrypsin to directly interact with C3a was next
assessed using biophysical methods. Speciﬁcally, the interaction be-
tween α-1-antitrypsin and C3a was assessed using (i) surface plasmon
resonance (SPR), where randomly biotinylated C3a was immobilized
via direct amine coupling to sensor chips and binding of α-1-antitrypsin
detected by Biacore T200; and (ii) Microscale Thermophoresis (MST)
performed using 0.5 μM NT-647 labelled recombinant α-1-antitrypsin
and 205 μM–6 nM C3a. SPR studies demonstrated an interaction of α-1-
antitrypsin with C3a (Fig. 3b), which was further validated by MST
(Fig. 3c) with good agreement between Kd values determined by the
two methods (7.53 μM and 8.4 μM respectively). Although this is a re-
latively moderate aﬃnity binding interaction, it is plausible that it is
S. Dimeloe et al. Journal of Steroid Biochemistry and Molecular Biology 189 (2019) 1–9
3
physiologically relevant given the high circulating levels of α-1-anti-
trypsin of around 20–48 μM [19].
3.4. α-1-Antitrypsin and C3a interact to promote CD4+ T cell IL-10
secretion
To establish the role for C3a in α-1-antitrypsin-induced IL-10 in
human CD4+ T cells, we undertook two complementary experimental
approaches. Firstly, we added exogenous C3a to cultures containing
recombinant α-1-antitrypsin. This resulted in signiﬁcant IL-10 produc-
tion (Fig. 4a), whilst not increasing IFN-γ levels (Fig. 4b). Secondly, C3a
was neutralized with a speciﬁc antibody in cultures of CD4+ T cells
stimulated in the presence of plasma- derived α-1-antitrypsin. These
experiments demonstrated that inclusion of an anti-C3a speciﬁc anti-
body, but not an isotype control antibody signiﬁcantly reduced IL-10
levels in (Fig. 4c), whilst again not aﬀecting IFN-γ secretion. These
experiments indicate that α-1-antitrypsin and C3a act in concert to
drive IL-10 secretion by CD4+ T cells.
3.5. α-1-Antitrypsin is required for 1,25(OH)2D3-induced IL-10
This work has identiﬁed that 1,25(OH)2D3-treatment promotes α-1-
antitrypsin expression by CD4+ T cells, and furthermore that α-1-an-
titrypsin, at circulating levels, acts together with its binding partner,
C3a, to promote IL-10 expression. We therefore next probed whether
the α-1-antitrypsin-C3a axis may play an endogenous role in
1,25(OH)2D3-driven IL-10 expression by CD4+ T cells. Despite being a
well-established eﬀect of 1,25(OH)2D3, with evidence for in vivo re-
levance, this remains poorly understood and the kinetics indicate a
likely indirect mechanism. To do so, we compared eﬀects of
1,25(OH)2D3 on SERPINA1 and IL10 expression in CD4+ T cells from
healthy volunteer donors with those from age-matched patients ex-
hibiting a genetic mutation in the SERPINA1 gene (PiZZ genotype),
which can transcribe the SERPINA1 gene, but cannot secrete the mu-
tant, polymerised protein. As expected, SERPINA1 mRNA levels were
similarly induced by 1,25(OH)2D3 treatment in healthy control and
PiZZ genotype CD4+ T cells (Fig. 5a). However, consistent with their
Fig. 1. 1,25(OH)2D3 drives α-1-antitrypsin expression by human peripheral CD4+ T cells, but not CD8+ T cells or monocytes.
(a&b) CD4+ T cells, or (c) CD8+ T cells (1× 106 in 1ml), in RPMI 10%FCS, were stimulated with anti-CD3 (1 μg/ml) and IL-2 (50 u/ml) for two rounds of seven
days, in presence of 1,25(OH)2D3 as indicated (a: n=9, b: n=4, c: n=4). (d) Human puriﬁed peripheral CD14+ monocytes (1×106 in 1ml), in RPMI 10%FCS,
were stimulated with LPS (500 ng/ml) for 48 h in presence of 10−7 M 1,25(OH)2D3 as indicated (n=4). α-1-Antitrypsin expression was assessed by (a) qPCR for
SERPINA1 mRNA and (b–d) ELISA. mRNA quantiﬁcation by qPCR was normalised to 18S transcription and is shown as a relative quantity (RQ) compared to
expression under control conditions in vitro. Data are summarised as mean ± SEM. (a) p value derives from Friedman’s non-parametric repeated measures test. *
p < 0.050 as assessed by Dunn’s paired post-test for multiple comparisons. (b) p values derive from a repeated measures ANOVA.
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genotype, reduced levels of α-1-antitrypsin protein synthesis by PiZZ
CD4+ T cells compared to control individuals are routinely detected in
our laboratory (Supplementary Fig. 3). Nevertheless, when the capacity
of 1,25(OH)2D3 to enhance gene expression of IL10 by CD4+ T cell
cultures was compared in these two cohorts, PiZZ CD4+ T cells were
found to have signiﬁcantly lower abundance of IL10 mRNA, which was
indeed not upregulated compared to untreated cells (Fig. 5b). Addi-
tional analyses of the relationship between SERPINA1 and IL10 gene
expression in 1,25(OH)2D3-treated CD4+ T cells identiﬁed a signiﬁcant
correlation was observed in cultures from healthy donors (r= 0.75;
p=0.02; n= 9), which was not observed in the α-1-antitrypsin-deﬁ-
cient patient cohort (r= 0.50; p= 0.14; n= 10) (Fig. 5c–d).
Taken together these data indicate that 1,25(OH)2D3 increases α-1-
antitrypsin expression by CD4+ T cells, which then acts in turn to
promote anti-inﬂammatory IL-10 expression by these cells.
Additionally, we identify a novel interaction between α-1-antitrypsin
Fig. 2. Human plasma-derived, but not recombinant α-1-antitrypsin promotes production of IL-10 and IFN-γ by human CD4+ T cells, which is independent
of anti-protease activity.
(a–f) CD4+ T cells (1×106 in 1ml) were stimulated with anti-CD3 (1 μg/ml) and IL-2 (50 u/ml) for 48 h without or with the indicated α-1-antitrypsin preparation or
protein control. (a–d) Human α-1-antitrypsin was commercially obtained (e–f) human α-1-antitrypsin was lab-puriﬁed (see Methods for further details). Cytokine
levels were assessed by CBA and are summarised as mean ± SEM. p values derive from (a–d, n= 8) paired t-tests and (e–f, n= 4) one-way ANOVA. * p < 0.05 and
*** p < 0.001 as assessed by paired t-test (a–d) or Bonferroni’s paired post-test for multiple comparisons (e–f). (g) 0–5 nM α-1 antitrypsin was pre-incubated with
chymotrypsin before the addition of 0.1 mM substrate N-succinyl-Ala-Ala-Pro-Phe P-nitroanilide and the inhibitory capacity of each α-1-antitrypsin preparation assed
by the 405 nm absorbance. Data is presented as 405 nM absorbance T10-T0 normalised to 1 against α-1-antitrypsin concentration.
Fig. 3. α-1-Antitrypsin and C3a directly interact.
(a) C3a content in commercial human plasma-derived and recombinant α-1-antitrypsin was assessed by CBA anaphylatoxin ﬂex set. (b–c) Direct physical interaction
of α-1-antitrypsin with C3a was identiﬁed using (b) surface plasmon resonance (SPR) and (ii) microscale thermophoresis (MST) methodology. Curve ﬁt analyses
indicated Kd values of 8.4 μM (b) and 7.5 μM (c).
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and complement C3a, which is critical for IL-10 induction. The model is
summarised in graphical form in Supplementary Fig. 4.
4. Discussion
This study identiﬁes a novel interaction in the human immune
system, between two ubiquitous mediators, α-1-antitrypsin and C3a,
which directly bind to each other, and at physiological concentrations
interact to drive anti-inﬂammatory IL-10 expression by CD4+ T cells.
Additionally, we show that 1,25(OH)2D3 is a key upstream regulator in
this axis, stimulating α-1-antitrypsin production by human CD4+ T
cells – a novel cellular source of this protein.
A number of similarities exist in the anti-inﬂammatory function of
α-1-antitrypsin and vitamin D. Deﬁciency of both α-1-antitrypsin and
vitamin D are associated with inﬂammation and autoimmunity [20,21].
Additionally, the airway is an environment where the immune-mod-
ulatory eﬀects of both α-1-antitrypsin and 1,25(OH)2D3 appear to be of
key importance. Beyond its critical anti-elastase function, clearly evi-
denced by the development of COPD in deﬁcient individuals, α-1-an-
titrypsin deﬁciency is also implicated in control of airway inﬂammation
since asthma symptoms are also reported in α-1-antitrypsin deﬁciency
[22–24]. Vitamin D deﬁciency is also implicated in airway immune
homeostasis, as in respiratory diseases, including asthma, epidemio-
logic associations exist between vitamin D insuﬃciency and worse
asthma control. Notably, the phenotype of vitamin D deﬁciency in se-
vere asthma, and in particular treatment refractory asthma is associated
with a neutrophilic proﬁle, an enhanced pro-inﬂammatory Th17 phe-
notype and impaired induction of anti-inﬂammatory IL-10 [25]. Neu-
trophils are also proposed to play a prominent role in lung disease as-
sociated with α-1-antitrypsin deﬁciency, and our unpublished data
demonstrate a signiﬁcantly increased frequency of pro-inﬂammatory
Th17 in these individuals (manuscript in preparation). As we already
discuss in the introduction to this paper, DeMeo et al. [12] report that
COPD progression in α-1-antitrypsin deﬁciency associated with IL-10
Fig. 4. C3a and α-1-antitrypsin cooperatively induce IL-10 in human CD4+ T cells.
CD4+ T cells were cultured for 48 h in serum-free medium, in the absence or presence of (a–b) recombinant α-1-antitrypsin (100 μg/ml) and/or C3a (100 ng/ml) as
indicated or (c–d) commercial human plasma-derived α-1-antitrypsin (500 μg/ml) with or without a C3a neutralising or isotype control (anti-C3a/IgG1, 5 μg/ml)
antibody. Cytokine secretion was assessed by CBA and presented as mean ± SEM. p values derived from a one-way ANOVA. * p < 0.05, ** p < 0.01 as assessed by
Bonferroni’s paired post-test for multiple comparisons (n=4).
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polymorphisms and α-1 antitrypsin replacement therapy increases cir-
culating IL-10 in these individuals. Hence a number of clear parallels
exist. The present study indicates that the similarity between α-1-an-
titrypsin and vitamin D deﬁciency may be explained by a biological link
between these two mediators – speciﬁcally that 1,25(OH)2D3 regulates
α-1-antitrypsin abundance and thereby its immune-modulatory prop-
erties (see model proposed in Supplementary Fig. 4). Further studies are
now warranted to interrogate the importance of this axis in tissue en-
vironments and in the context of inﬂammation.
Previous reports have demonstrated anti-inﬂammatory actions of α-
1-antitrypsin in vitro and in experimental models in vivo [9], with early
papers for example reporting that α-1-antitrypsin therapy induces an-
tigen-speciﬁc immune tolerance during islet allograft transplantation in
mice [11,26]. The authors implicated a role for α-1-antitrypsin in
maintaining dendritic cells in an immature state and in the induction of
regulatory T cells (Treg), as assessed by increased mRNA for foxp3,
cytotoxic T lymphocyte antigen-4, TGF-beta, IL-10, and IL-1 receptor
antagonist. These functions closely mirror those described for vitamin D
(1,25(OH)2D3) on immune cells [4,6,27]. In the present study we fo-
cused on the capacity of α-1-antitrypsin to enhance IL-10 synthesis by T
cells since a major interest of the lab has been the control of IL-10
synthesis by 1,25(OH)2D3 [4,5]. A limitation of the current study is that
we did not comprehensively address whether Foxp3 expression was also
enhanced in these experiments, in part due to our earlier work showing
that 1,25(OH)2D3 increases the frequency of distinct IL-10 or Foxp3
expressing CD4+ T cells, with little or no co-expression [3]. However,
we did observe a reduced expression of FOXP3 mRNA in CD4+ T cells
obtained from PiZZ compared to control donors (data not shown: n=5
per group; p=0.0079). Furthermore, Mueller et al. [28] demonstrated
that a single intramuscular administration of recombinant adeno-asso-
ciated virus serotype 1 alpha-1 antitrypsin vector into alpha-1 deﬁcient
patients resulted in an active Treg response (approx. 10% of CD3+ cells
were Foxp3 up to 5-years post administration, which was not seen in
normal control muscle), suggesting future directions for our work.
The present study was able to compare responsiveness to
1,25(OH)2D3 in healthy control subjects versus those with a hereditary
deﬁciency of α-1-antitrypsin protein, characterised by the PiZZ geno-
type, who possess around only 15% of normal wildtype circulating α-1-
antitrypsin protein. Whilst CD4+ T cells from healthy subjects de-
monstrated a signiﬁcant positive correlation between the capacity of
1,25(OH)2D3 to increase gene expression for IL10 and SERPINA1, this
association was absent in the α-1-antitrypsin deﬁcient donors. This
comparison of the response to 1,25(OH)2D3 in α-1-antitrypsin deﬁcient
versus control subjects strengthen evidence implicating 1,25(OH)2D3 as
an upstream regulator of this anti-inﬂammatory axis in these cells.
There appear to be a growing number of underlying mechanisms by
which α-1-antitrypsin exerts immunomodulatory activity, which re-
main poorly understood (reviewed in 9). However, the anti-protease
function of α-1-antitrypsin is not consistently reported to be required,
and precedence exists for functions of α-1-antitrypsin that require
binding to other serum components [9]. For example Bergin et al. [29]
described the capacity of α-1-antitrypsin to regulate chemotaxis in-
duced by soluble immune complexes and IL-8 by human neutrophils.
Speciﬁcally, α-1-antitrypsin decreased the chemotactic response of
Fig. 5. α-1-Antitrypsin is required for
1,25(OH)2D3-induced IL-10 expression by
CD4+ T cells.
CD4+ T cells (1× 106 in 1ml) were stimulated
with anti-CD3 (1 μg/ml) and IL-2 (50 u/ml) in
the absence or presence of 100 nM
1,25(OH)2D3 for 7 days. (a, c–d) SERPINA1
and (b, c–d) IL10 mRNA quantiﬁcation by
qPCR in 1,25(OH)2D3-treated cells was nor-
malised to 18 s expression and is shown as a
relative quantity (RQ) compared to expression
of cells stimulated in the absence of
1,25(OH)2D3. (c–d) Each dot shows relative
expression of both genes in individual (c)
healthy and (d) PiZZ subjects. (a–b) *
p < 0.05 as assessed by paired t-test. (c–d)
Correlation between vitamin D regulation of
SERPINA1 and IL-10 was assessed using a
Pearson test (Healthy n= 9, PiZZ n=10).
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CXCR1 signaling by binding IL-8 and inhibiting receptor engagement.
In a very diﬀerent example, additional protease-independent activity of
α-1-antitrypsin was suggested by studies describing the induction by α-
1-antitrypsin of angiopoietin-like protein 4 in human blood monocytes
and lung microvascular endothelial cells [30]. This function of α-1-
antitrypsin required binding to the fatty acids linoleic acid and oleic
acid. Linoleic acid was also reported to enhance the capacity of α-1-
antitrypsin to inhibit LPS-induced IL-1β synthesis by human neutrophils
[31]. Thus our demonstration that induction of IL-10 in CD4+ T cells by
α-1-antitrypsin is dependent on binding to the complement component
C3a, adds to this growing body of evidence for protease-independent
functions of α-1-antitrypsin.
C3a is shown to be critical to one of the major anti-inﬂammatory
functions of α-1-antitrypsin. In addition to its key innate immune
function, the complement system is now recognized to be involved in
both the generation and regulation of adaptive immunity. C3a and C5a
are essential for induction of inﬂammatory adaptive immune responses,
signaling via their surface G-protein coupled receptors [17]. The com-
plement system also promotes immune tolerance and drives IL-10, for
example via ligation of CD46 [32]. The anti-inﬂammatory role we have
identiﬁed for C3a in promoting IL-10 synthesis initially appears in
contrast to its well-known pro-inﬂammatory eﬀects, as highlighted by
the impaired immunity associated with C3 deﬁciency [33]. However it
is consistent with recent, apparently opposing observations of immune
dysregulation,failure of immune tolerance mechanisms and allograft
rejection in C3 and C3aR deﬁcient animal models [34,35] and with
observations in humans thatpuriﬁed CD4+ T cells from C3 deﬁcient
individuals demonstrate defective IL-10 responses in vitro [36]. Indeed,
complement has been described as a “double-edged sword” in the
regulation of immunity [37]. The dependency upon C3a for the anti-
inﬂammatory eﬀects of α-1-antitrypsin in vivo in disease models re-
mains to be assessed using relevant transgenic systems.
Our study identiﬁes 1,25(OH)2D3 as an upstream regulator of α-1-
antitrypsin expression in human T cells. The major source of circulating
α-1-antitrypsin is hepatocytes, although other cell types synthesise this
protein. This includes monocyte-derived macrophages and dendritic
cells, alveolar macrophages, bronchial epithelial cells and neutrophils,
which may signiﬁcantly contribute to local α-1-antitrypsin levels in the
context of an immune response. However, to date we have found no
evidence for regulation by 1,25(OH)2D3 of α-1-antitrypsin gene and/or
protein levels in monocytes, respiratory epithelial cells or primary he-
patocytes (data not shown). Our interpretation of these data is that this
function of 1,25(OH)2D3 may therefore reﬂect an im-
munoregulatory–speciﬁc activity of 1,25(OH)2D3 in human T cells,
adding to the growing list of such functions attributed to 1,25(OH)2D3
[1,38].
Growing recognition of vitamin D deﬁciency and insuﬃciency in
recent years and its association with a wide range of immune-mediated
pathologies, has meant that pharmacological vitamin D supplementa-
tion (with precursors of 1,25(OH)2D3) is now increasingly employed
[1,38]. It is known to be safe, well-tolerated, relatively inexpensive and
with a half-life of weeks. A number of clinical studies of vitamin D
supplementation, with highly diﬀering design and primary outcomes,
have been performed. Notably, systematic review of these trials to date,
indicate that vitamin D is beneﬁcial in asthma [27]. Understanding the
mechanisms whereby vitamin D acts to promote respiratory health are
therefore likely to be important in improving clinical trial design. To
date, the capacity of vitamin D to promote antimicrobial pathways, a
common cause of asthma exacerbations, together with induction and/
or maintenance of immune tolerance pathways are proposed [25]. In
addition we, and others, have proposed that vitamin D beneﬁcially
modulates immune and clinical response to glucocorticoids. In early
studies we demonstrated that 1,25(OH)2D3 restored the impaired
steroid-induced IL-10 response in steroid refractory asthma patients
both in vitro and in vivo [5], and clinical studies now provide evidence
for modest steroid-sparing eﬀects on vitamin D in asthma patients
(reviewed in [25]). A very recent report of α-1-antitrypsin infusion
therapy for steroid-resistant graft-versus-host disease suggested that α-
1-antitrypsin was safe and potentially eﬀective in treating these pa-
tients, and was associated with an increased ratio of regulatory to ef-
fector T cells following treatment [39], further demonstrating parallels
with known eﬀects of vitamin D.
α-1-antitrypsin has been used successfully in animal models of
various autoimmune diseases as well as transplantation [9], and this
has contributed to the growing interest in the therapeutic application of
α-1-antitrypsin as an anti-inﬂammatory mediator, beyond its applica-
tion in AAT deﬁciency. In addition to the above example in graft-
versus-host disease, clinical studies of the safety and eﬃcacy of α-1-
antitrypsin treatment have been reported in conditions as diverse as
type 1 diabetes [40], lung transplantation and acute myocardial in-
farction ([41]; see also clincialtrials.gov).
In summary, we have identiﬁed a novel, vitamin D (1,25(OH)2D3)
controlled regulatory axis in the immune system, mediated through the
interaction of α-1-antitrypsin and the complement anaphylatoxin C3a
to stimulate IL-10 synthesis by CD4+ T cells. Our data highlight a novel
potential therapeutic application for vitamin D in modulation of this
axis, and suggest new roles for α-1-antitrypsin in the control of in-
ﬂammatory disease. There is wide experience of the use of both vitamin
D and α-1-antitrypsin as therapeutic agents in the US and Europe and
both have very good safety proﬁles. Future trials oﬀer the capacity to
directly examine evidence for the role of α-1-antitrypsin in vitamin D-
mediated immune regulation.
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